Incyte’s Opzelura Nears EU Approval for Eczema Treatment

The recommendation stems from successful Phase 3 clinical trials, marking a significant step for the biopharmaceutical company as it seeks to expand its reach. For patients struggling with atopic dermatitis—a chronic inflammatory condition affecting roughly 4% of the global adult population—the drug offers a potential alternative to existing regimens.

Following the agency's opinion, the European Commission now holds the final authority to grant authorization. If approved, this would represent the second indication for Opzelura within the bloc, building on its existing clearance for treating non-segmental vitiligo in adults and adolescents. Investors reacted to the news with optimism, sending Incyte shares up 1.7% to $109.36 in premarket trading on the Nasdaq, extending a rally that has seen the stock gain 17% over the past three months.